Table 1.
Independent predictors of laboratory monitoring following combination antiretroviral therapy initiation by laboratory category, CFAR Network of Integrated Clinical Systems, between 2000 and 2010.
| First Laboratory Test* | Repeated Tests* | |
|---|---|---|
| HR (95% CI) | HR (95% CI) | |
| Hematologic Tests | ||
| Age (by decade increase) | 1.06 (1.03, 1.10) | 1.03 (1.00, 1.05) |
| Female Sex | - | 1.02 (0.95, 1.09) |
| MSM | - | 1.01 (0.96, 1.06) |
| IDU | 0.73 (0.64, 0.84) | - |
| CD4 count (by 100 cells/mm3 increase) | 0.94 (0.92, 0.97) | 0.99 (0.97, 1.01) |
| Viral load (by log10 increase) | 1.01 (0.96, 1.07) | 1.00 (0.96, 1.03) |
| AIDS Diagnosis | 1.28 (1.18, 1.39) | 1.24 (1.16, 1.31) |
| cART start year | 1.00 (0.99, 1.02) | 1.00 (0.99, 1.02) |
| Boosted-PI (compared to NNRTI) | 1.18 (1.10, 1.26) | 1.12 (1.07, 1.17) |
| Zidovudine Use | - | 1.10 (0.97, 1.25) |
| Tenofovir Use | 1.01 (0.91, 1.13) | 1.05 (0.93, 1.19) |
| Abacavir Use | 1.32 (1.16, 1.51) | 1.27 (1.14, 1.42) |
| Hepatitis C | - | 1.13 (1.05, 1.22) |
| Hypertension | - | 1.11 (1.01, 1.21) |
| Hyperglycemia | 1.13 (0.99, 1.30) | 1.04 (0.99, 1.10) |
| Hepatic Tests | ||
| Age (by decade increase) | 1.07 (1.03, 1.11) | 1.04 (1.01, 1.06) |
| Female Sex | - | 1.07 (0.99, 1.15) |
| Race/Ethnicity | ||
| White | Ref. | Ref. |
| Black | 0.92 (0.85, 1.00) | 0.93 (0.88, 0.98) |
| Other | 1.06 (0.97, 1.16) | 1.05 (0.98, 1.13) |
| MSM | 1.12 (1.04, 1.21) | 1.02 (0.97, 1.07) |
| IDU | 0.85 (0.73, 0.98) | - |
| CD4 count (by 100 cells/mm3 increase) | 0.95 (0.92, 0.97) | 0.97 (0.96, 0.98) |
| Viral load (by log10 increase) | 0.97 (0.92, 1.02) | 0.99 (0.95, 1.02) |
| AIDS Diagnosis | 1.33 (1.22, 1.44) | 1.22 (1.15, 1.30) |
| cART start year | - | 1.01 (1.00, 1.02) |
| Boosted-PI (compared to NNRTI) | 1.23 (1.14, 1.32) | 1.15 (1.10, 1.21) |
| Zidovudine Use | 1.16 (0.94, 1.43) | - |
| Tenofovir Use | 1.38 (1.10, 1.71) | 1.00 (0.93, 1.08) |
| Abacavir Use | 1.53 (1.28, 1.82) | 1.26 (1.16, 1.37) |
| Hepatitis B | 1.10 (0.95, 1.29) | - |
| Hepatitis C | 0.95 (0.85, 1.05) | 1.02 (0.93, 1.12) |
| Hypertension | - | 1.09 (1.00, 1.18) |
| Hyperglycemia | 1.19 (1.03, 1.36) | 1.03 (0.98, 1.09) |
| Renal Tests | ||
| Age (by decade increase) | 1.06 (1.03, 1.10) | 1.04 (1.01, 1.07) |
| Female Sex | - | 1.02 (0.92, 1.13) |
| Race | ||
| White | Ref. | |
| Black | - | 0.95 (0.88, 1.03) |
| Other | - | 1.07 (0.97, 1.18) |
| MSM | - | 0.96 (0.89, 1.04) |
| IDU | 0.77 (0.67, 0.88) | - |
| CD4 count (by 100 cells/mm3 increase) | 0.95 (0.93, 0.97) | 0.95 (0.93, 0.97) |
| Viral load (by log10 increase) | 0.98 (0.93, 1.03) | 0.96 (0.91, 1.01) |
| AIDS Diagnosis | 1.29 (1.19, 1.40) | 1.37 (1.27, 1.49) |
| cART start year | 1.01 (1.00, 1.03) | 1.01 (1.00, 1.03) |
| Boosted-PI (compared to NNRTI) | 1.13 (1.05, 1.22) | 1.14 (1.06, 1.22) |
| Zidovudine Use | 1.14 (0.92, 1.42) | - |
| Tenofovir Use | 1.41 (1.13, 1.75) | 1.01 (0.91, 1.13) |
| Abacavir Use | 1.58 (1.32, 1.89) | 1.21 (1.07, 1.36) |
| Hepatitis C | - | 1.03 (0.93, 1.14) |
| Hypertension | 1.06 (0.97, 1.15) | 1.08 (1.01, 1.16) |
| Hyperglycemia | 1.21 (1.05, 1.39) | 1.20 (1.04, 1.39) |
| Lipid Tests | ||
| Age (by decade increase) | 1.02 (0.97, 1.07) | 1.02 (0.98, 1.06) |
| Race/Ethnicity | ||
| White | Ref. | Ref. |
| Black | 1.09 (0.98, 1.21) | 0.90 (0.82, 0.99) |
| Other | 0.88 (0.77, 1.01) | 0.92 (0.83, 1.03) |
| IDU | - | 1.01 (0.84, 1.21) |
| CD4 count (per 100 cells/mm3 increase) | 0.95 (0.93, 0.98) | - |
| AIDS Diagnosis | 1.14 (1.02, 1.28) | - |
| cART start year | 1.06 (1.04, 1.09) | 1.02 (1.00, 1.05) |
| Zidovudine Use | 1.09 (0.93, 1.28) | - |
| Tenofovir Use | - | 1.07 (0.94, 1.23) |
| Abacavir Use | 1.21 (1.03, 1.43) | 1.52 (1.30, 1.77) |
| Hepatitis C | - | 0.94 (0.83, 1.07) |
| Hypertension | 1.14 (1.02, 1.29) | - |
| Hyperglycemia | 1.22(1.00, 1.47) | 1.11 (0.96, 1.27) |
*
multivariable regression includes all variables predictive in bivariable analysis (all variables with results in column) as well as study site.
HR=hazard ratio; MSM=men who have sex with men; IDU=injection drug user; cART=combination antiretroviral therapy; PI=protease inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor